From ideas...to medical applications
In the absence of any straightforward laboratory tests, the most severe complication, known as type II heparin-induced thrombocytopenia (HIT) has...
From ideas...to medical applications
Midway between plasma haemostasis and cellular haemostasis are microparticles, rich in procoagulant phospholipids. An increase in this procoagulant...
From ideas...to medical applications
Listening to and exchanging ideas with members of the biomedical science community has enabled Stago to develop its expertise in the search for...
From ideas...to medical applications
Achieving a balanced policy with regard to investment in research & development (R&D), technological monitoring and rational acquisitions is a key...
June 29th - July 4th, 2013
July 28 - August 1, 2013
December 7 - 10, 2013
This 
free educational application in English is the first of its kind and has been developed by an expert in Haemostasis… Stago.
New range of STA®-Routine QC quality control plasmas: The best range for routine laboratory tests
To fulfil regulatory requirements, laboratories must perform regular internal quality control (IQC) on at least two concentration levels (normal and abnormal) to check and confirm the performance of their testing systems.
In 1977, with Bjarne Østerud, Dr. S.I. Rapaport described the activation of factor IX by factor VIIa/tissue factor complex as an additional pathway in the initiation of blood coagulation.
